Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Queensland Health
QuintilesIMS
Dow
Colorcon
Cantor Fitzgerald
Medtronic
Express Scripts
Healthtrust
Federal Trade Commission

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,187,405

« Back to Dashboard

Which drugs does patent 9,187,405 protect, and when does it expire?

Patent 9,187,405 protects GILENYA and is included in one NDA.

This patent has twenty-five patent family members in twelve countries.
Summary for Patent: 9,187,405
Title:S1P receptor modulators for treating relasping-remitting multiple sclerosis
Abstract: The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X ##STR00001## for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
Inventor(s): Hiestand; Peter C. (Austria, CH), Schnell; Christian (Hesingue, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:14/257,342
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,187,405

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis GILENYA fingolimod CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF AUTOIMMUNE DISEASE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,187,405

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0612721.1Jun 27, 2006

Non-Orange Book US Patents Family Members for Patent 9,187,405

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,741,963 S1P receptor modulators for treating multiple sclerosis ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,187,405

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011201844 ➤ Subscribe
Australia 2013200356 ➤ Subscribe
Australia 2016266058 ➤ Subscribe
Brazil PI0713985 ➤ Subscribe
Canada 2653569 ➤ Subscribe
China 101478961 ➤ Subscribe
China 103550195 ➤ Subscribe
European Patent Office 2037906 ➤ Subscribe
European Patent Office 2698154 ➤ Subscribe
European Patent Office 2959894 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
Cerilliant
Healthtrust
Express Scripts
AstraZeneca
Baxter
McKesson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot